Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections

Blood

Volumn 90, Issue 8, 1997, Pages 3098-3105

  Miller, Jeffrey S ^a,b   Prosper, Felipe ^a   McCullar, Valarie ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD2 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 2;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CULTURE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXICITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030873666     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.8.3098     Document Type: Article

References (41)

1. Goodman JW, Hodgson GS: Evidence for stem cells in the peripheral blood of mice. Blood 19:702, 1962
2. Storb R, Graham TC, Epstein RB, Sale GE, Thomas FD: Demonstration of hematopoietic stem cells in the peripheral blood of baboons by cross circulation. Blood 50:537, 1977
3. McCredie KB, Hersh EM, Freireich EJ: Cells capable of colony formation in the peripheral blood of man. Science 171:293, 1970
4. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85:1655, 1995
5. Koc H, Gurman G, Arslan O, Ozcan M, Akan H, Ilham O, Konuk N, Beksac M, Uysal A: Is there an increased risk of graft-versus-host disease after allogeneic peripheral blood stem cell transplantation? Blood 88:2362, 1996
6. Marmont A, Horowitz M, Gale R, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, Rimm AA, Ringden O, Speck B, Wiener RS, Bortin MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120, 1991
7. Ruvollo P, Bright E, Kennedy MJ, Morris L, Fischer A, Vogelsang G, Jones R, Hes A: Cyclosporine-induced autologous graft versus host disease: Assessment of cytolytic effector mechanisms and the v-beta T-cell receptor repertoire. Transplant Proc 27:1363, 1995
8. Mackinnon S, Bungey J, Chase A, Paulsen W, Hows JM, Goldman JM: Origin and function of adherent lymphokine activated killer cells in patients with chronic myeloid leukemia who relapse following bone marrow transplantation. Br J Haematol 77:60, 1991
9. Mackinnon S, Hows JM, Goldman JM: Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood 76:2037, 1990
10. Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J, Burns LJ: Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant 3:34, 1997
11. Charak BS, Brynes RK, Groshen S, Chen SC, Mazumder A: Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 76:2187, 1990
12. Verma UN, Areman E, Dickerson SA, Kotula RS. Mazumder A: Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors. Bone Marrow Transplant 15:199, 1995
13. Meeham KR, Rajagopal C, Verma UN, Frankel SR, Cahill R, Areman EA, Foelber R, Lippman ME, Mazumder A: Biologic and clinical correlates of interleukin-2 (IL-2) administration in peripheral blood stem cell (PBSC) transplantation for breast cancer. Blood 86:387a, 1995 (suppl 1, abstr)
14. - primitive progenitors in long-term bone marrow culture. Blood 80:2182, 1992
15. + NK progenitor. Blood 83:2594, 1994
16. Galy A, Travis M, Cen D, Chen B: Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 3:459, 1995
17. + marrow progenitors give rise to both NK and T cells when circulated in the presence of lineage specific microenvironments. Blood 84:419a, 1994 (suppl 1, abstr)
18. Widman FK: Standards for Blood Bank and Transfusion Services (ed 15). Bethesda, MD, American Association of Blood Banks, 1993
19. Prosper F, Stroncek D, Verfaillie CM: Phenotypic and functional characterization of long-term culture-initiating cells present in peripheral blood progenitor collections of normal donors treated with granulocyte-stimulating factor. Blood 88:2033, 1996
20. Nagler A, Lanier LL, Cwirla S, Phillips JH: Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 143:3183, 1989
21. + lymphokine-activated killer cells. J Immunol 142:2949, 1989
22. Pierson BA, McGlave PB, Hu WS, Miller JS: Natural-killer cell proliferation is dependent on human serum and is markedly increased utilizing an enriched supplemented basal medium. J Hematother 4:149, 1995
23. Miller JS, Oelkers S, Verfaillie C, McGlave PB: Role of monocytes in the expansion of human activated natural killer cells. Blood 80:2221, 1992
24. Pierson BA, Gupta K, Hu WS, Miller JS: Human natural killer cell expansion is regulated by thrombospondin-mediated activation of TGF-β1 and independent accessory cell-derived contact and soluble factors. Blood 87:180, 1996
25. Porter EH, Berry RJ: The efficient design of transplantable tumor assays. J Cancer 17:583, 1963
26. Taswell C: Limiting dilution assays for the determination of immunocompetent cell frequencies: I. Data analysis. J Immunol 126:1614, 1981
27. Talmadge JE, Singh RK, Ageitos A, Ozerol I, Ino K: T cell apoptosis (mediated in part by FAS ligand) by monocytes in cytokine mobilized stem cell products: Resultant immunosuppression. Blood 88:610a, 1996 (suppl 1, abstr)
28. Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE: Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 79:2849, 1992
29. Bensinger W, Singer J, Appelbaum F, Lilleby K, Longin K, Rowley S, Clarke E, Clift R, Hansen J, Shields T, Storb R, Weaver C, Weiden P, Buckner CD: Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 81:3158, 1993
30. Talmadge JE, Reed EC, Kessinger A, Kuszynski CA, Perry GA, Cordy CL, Mills KC, Thomas ML, Pirruccello SJ, Letheby BA, Arneson MA, Jackson JD: Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 17:101, 1996
31. +dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli which recruit clonogenic NK, and exhibit decreased proliferation on a per cell basis. Blood 88:2279, 1996
32. Prosper F, Stroncek D, Verfaillie C: Homing of mobilized PBPC, which adhere poorly to stroma due to low levels of VLA-4, may result from upregulation of expression and function of VLA-4 once PBPC are removed from the "mobilizing" milieu. Blood 88:475a, 1996 (suppl 1, abstr)
33. Verfaillie CM, McCarthy JB, McGlave PB: Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 90:1232, 1992
34. Gordon MY, Dowding CR, Riley MP, Goldman JP, Greaves MF: Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myelogenous leukemia. Nature 328:342, 1984
35. Silva MRG, Parreira A, Ascensao JL: Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: Conditions for in vitro expansion. Exp Hematol 23:1676, 1995
36. Roberts MM, To LB, Gillis D, Mundy J, Rawling C, Ng K, Juttner CA: Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 12:469, 1993
37. Verbik DJ, Jackson JD, Pirruccello SJ, Patil KD, Kessinger A, Joshi SS: Functional and phenotypic characterization of human peripheral blood stem cell harvests: A comparative analysis of cells from consecutive collections. Blood 85:1964, 1995
38. Richard C, Alsar MJ, Calavia J, Bello-Fernandez Baro J, Loyola I, Rios R, Cuadrado MA, Gonzalez-Pardo C, Iriondo A, Conde E, Zubizarreta A: Recombinant human GM-CSF enhances T cell-mediated cytotoxic function after ABMT for hematological malignancies. Bone Marrow Transplant 11:473, 1993
39. Taga T, Kariya Y, Shimada M, Uchida A: Suppression of natural killer cell activity by granulocytes in patients with aplastic anemia: Role of granulocyte colony-stimulating factor. Immunol Lett 39:65, 1993
40. Shibuya A, Taguchi K, Kojima H, Abe T: Inhibitory effect of granulocyte-macrophage colony-stimulating factor therapy on the generation of natural killer cells. Blood 78:3241, 1991
41. Taguchi K, Shibuya A, Inazawa Y, Tsukasa A: Suppressive effect of granulocyte-macrophage colony-stimulating factor on the generation of natural killer cells in vitro. Blood 79:3227, 1992